Additional experiments are warranted using modulators of ARA metabolism and downstream signaling, such as specific inhibitors of LOX or CYP450 ω-hydroxylase as well as prostanoid receptor antagonists, to decipher if these approaches may restore cardiovascular homeostasis in HTN with the expected results of improving the prognosis of patients. This evidence concerns the gene LOX and hypertensive disorder.